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The levels of brain-derived neurotrophic factor (BDNF) are significantly decreased
in patients with schizophrenia and correlate with impairments in cognitive function.
However, no study has investigated the relationship between the serum BDNF levels
and decision-making. We compared patients with schizophrenia to healthy controls
with respect to their decision-making ability and serum BDNF levels. Eighty-six chronic
schizophrenia patients and 51 healthy controls participated in this study. We controlled
for gender, age, and estimated intelligence quotient (IQ), and we investigated the
differences in decision-making performance on the Iowa Gambling Task (IGT) between
the schizophrenia patient and control groups. We also compared the IGT scores, the
serum BDNF levels, and the clinical symptoms between the groups. The IGT scores of the
schizophrenia patients were lower than those of the controls. A negative correlation was
detected between the mean net scores on the trials in the final two blocks and the serum
BDNF levels (p < 0.05). Multiple regression analysis revealed that depressive symptoms
and the serum BDNF levels were significantly associated with the mean net scores on the
trials in the final two blocks. Based on these results, impaired sensitivity to both reward
and punishment is associated with depressive symptoms and reduced serum BDNF levels
in chronic schizophrenia patients and may be related to their poor performance on the IGT.
Keywords: brain-derived neurotrophic factor, decision-making, schizophrenia, gambling task, cognition,
depression
INTRODUCTION
Brain-derived neurotrophic factor (BDNF), is a member of neu-
rotrophins involved in growth, differentiation, maturation, and
survival in immature neurons. In mature neurons, it plays an
important role in synaptic plasticity, augmentation of neuro-
transmission and regulation of receptor sensitivity (Numakawa
et al., 2010). BDNF and its high affinity receptor TrkB are widely
expressed in developing and adult nervous system, and BDNF is
the most abundantly expressed neurotrophic factor in the cen-
tral nervous system (Balaratnasingam and Janca, 2012). Recent
research has provided evidence for the contribution of BDNF
to the pathophysiology of schizophrenia. Studies of the BDNF
Val66Met (rs6265) showed that the Met allele is associated with
lower levels of BDNF secretion and with abnormal hippocam-
pal structure and function, providing evidence for the direct
involvement of BDNF in schizophrenia (Egan et al., 2003).
Recent advances in clinical neuroscience indicate that the hip-
pocampus and the orbitofrontal cortex (OFC) play a critical role
in complex decision-making processes (Rolls, 1999; Krawczyk,
2002; Johnson et al., 2007; Yu and Fank, 2014). Patients experi-
encing damage to the hippocampus and the OFC exhibit striking
deficits in real-life decision-making, especially social or emotional
decision-making, in the context of generally well-preserved intel-
lectual functioning. In addition, growing evidence demonstrates
that schizophrenia patients exhibit emotional disturbances and
social dysfunction (Mandal et al., 1999; Kohler et al., 2000;
Chemerinski et al., 2002), which could be partially explained by
impaired decision-making. This impairment in decision-making
may occur during interpersonal interactions and social situa-
tions (Damasio, 1994). In general, decisions are made based on
the assessment of reward and punishment outcomes using both
cognitive and affective information (Solms and Turnbull, 2004).
The Iowa Gambling Task (IGT) was developed to assess the
role of affective information in decision-making (Bechara et al.,
1994). In this task, subjects are presented with four decks of cards
and are asked to select any deck in any sequence, and then to
take a card from it. The subjects win or lose money with each
turn of a card. The participants do not appear to understand the
contingencies of the game at the onset. Nevertheless, they can
quite rapidly develop a “feeling,” or “hunch” in the absence of
conceptual awareness.
Because cognitive dysfunction is associated with schizophre-
nia, we hypothesized that the serum BDNF levels are associated
with the IGT scores of the chronic schizophrenia patients.
MATERIALS AND METHODS
SUBJECTS
Eighty-six chronic schizophrenia outpatients recruited from the
University of Occupational and Environmental Health partic-
ipated in the present study and met the following inclusion
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criteria: (1) aged 20–60 years; (2) chronic illness without acute
exacerbation; and (3) continuously receiving a stable dose of
antipsychotics for at least 3 months. The exclusion criteria were:
(1) any comorbid central nervous system disorder; (2) severe psy-
chotic symptoms; (3) meeting the DSM-IV criteria for alcohol or
other substance dependence; (4) meeting the DSM-IV criteria for
mental retardation; (5) receiving antidepressants; (6) treatment
with electroconvulsive therapy in the 6 months preceding the
study; (7) receiving clozapine; and (8) inability to understand the
study protocol. The diagnosis of schizophrenia was established
based on the Structured Clinical Interview for DMS-IV (SCID)
(First et al., 1996) and a comprehensive review of the patients’
medical records. All patients met the criteria for schizophre-
nia. None were comorbid with any other psychiatric disorders.
Seventy-eight of the schizophrenia patients were receiving stable
dose of one antipsychotic drug (risperidone, olanzapine, queti-
apine, aripiprazole, blonanserin, or perospirone). The remaining
schizophrenia patients were receiving at least two antipsychotic
drugs. Regarding other medications, nine patients were taking
stable dosages of mood stabilizer (lithium, valproic acid, or car-
bamazepine), five were taking stable dosages of anticholinergic
drugs and two were taking antidepressant (paroxetine or mirtaza-
pine). Schizophrenic symptoms were rated using the Positive and
Negative Syndrome Scale (PANSS) (Kay et al., 1987).
Additionally, we recruited 51 healthy volunteers (26 females
and 25 males) for the healthy control group. The healthy controls
consisted of individuals matched to the patients with respect to
age, gender, and estimated intelligence quotient (IQ). The healthy
controls had not experienced a head injury and did not suffer
from any neurologic, psychotic, mood, or substance use disorder
as evaluated by the SCID.
INTELLIGENCE TEST
The IQ of the participants was estimated using the Japanese Adult
Reading Test (Matsuoka et al., 2002; Hori et al., 2008), a Japanese
version of the National Adult Reading Test (Nelson and Wilson,
1991), and those individuals exhibiting estimated IQ scores of less
than 80 were excluded from this study.
IGT
Decision-making ability was assessed using the computerized ver-
sion of the IGT in Japanese (Bechara et al., 1994, 1999, 2005).
Decks of cards labeled “A,” “B,” “C,” or “D” were placed in front
of the subjects from left to right. Initially, 200,000 yen were given
to each subject. The subjects were told that (1) they are to draw
one playing card from one of the four decks on each turn, (2)
this game involves betting across multiple turns, (3) they receive
money every time that they draw a card but that a penalty is occa-
sionally applied, and (4) the objective of this game is to maximize
the amount of money that they have. When selecting a card, the
subjects can draw a card from any of the decks and can change
their selection any time as many times as they choose. The game
ended at the 100th draw of a card by a subject, but the sub-
jects were not informed about this rule beforehand. The subjects
received a reward each time they drew a card; if they selected a
card from the deck A or B, a reward of 10,000 yen was applied,
and if they selected a card from the deck C or D, a reward of
5000 yen was applied. Simultaneously, a penalty is applied; decks
A and B are referred to as “bad decks” because the immediate
reward at the time of the draw is high but the penalty is also
high and frequent; therefore, the player ultimately loses money
as cards are drawn from these decks. Alternatively, decks C and D
are referred to as the “good decks” because the immediate reward
is low but the frequency and amount of the penalty is low; there-
fore, players who draw cards from these decks ultimately earn
money. Additionally, decks A and C are categorized as “low mag-
nitude decks” in which a low penalty is applied at a relatively high
frequency, whereas decks B and D are categorized as “high mag-
nitude decks” in which a high penalty is applied at a relatively low
frequency. The task ended after 100 selections. Neither the risks
of rewards or penalties for each deck nor the number of selec-
tions allowed was disclosed to the subjects. The composition of
the final score and the total amount of money held by each sub-
ject at the end of the task was not disclosed to the subjects. This
score represented the extent to which socially valuable resources
had been increased and may also indicate the amount of risk that
the subject was willing to accept given that they may have contin-
ued to lose. The frequency of shifting between advantageous (C
and D) and disadvantageous (A and B) decks by the subject was
computed for every 20 cards, for a total of 5 blocks.
This examination is an exercise in which the subjects are
rewarded as well as occasionally penalized with each draw of a
card. The subjects can learn the types of rewards and penalties
that are applied and can evaluate and change their selections dur-
ing the process of the game. In this examination, the subjects must
use cognitive processing to predict outcomes associated with their
selection of cards and generate future predictions using a complex
set of results and repeated decisions.
BDNF MEASUREMENT
All blood samples were obtained between 7:00 and 10:00 a.m. in
themorning fasting. Fifteenmilliliters of venous blood was drawn
with subjects in the supine position, after the subjects had been
lying at rest overnight.
The serum BDNF levels were measured using a BDNF Emax
Immunoassay Kit (Promega, Madison,WI, USA) according to the
manufacturer’s instructions. In short, 96-well microplates were
coated with an anti-BDNF monoclonal antibody and incubated
at 4◦C for 18 h. The plates were incubated in a blocking buffer for
1 h at room temperature. The samples were diluted 100 times with
assay buffer, and BDNF standards were maintained at room tem-
perature under horizontal shaking for 2 h, followed by washing
with the appropriate washing buffer. The plates were incubated
with anti-human BDNF polyclonal antibody at room tempera-
ture for 2 h and washed with the washing buffer. Then, the plates
were incubated in an anti-IgY antibody conjugated to horseradish
peroxidase for 1 h at room temperature, followed by incuba-
tion in peroxidase substrate and a tetramethylbenzidine solution
to induce a colorized reaction. This reaction was stopped using
1mol/L hydrochloric acid. The absorbance at 450 nm was mea-
sured using an Emax automated microplate reader. The measure-
ments were performed in duplicate. The standard curve was linear
from 5 to 5000 pg/mL, and the detection limit was 10 pg/mL. The
intra- and inter-assay coefficients of variation were 5 and 7%,
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respectively. The recovery rate of exogenously added BDNF to the
measured plasma samples was more than 95%.
Written informed consent was obtained from all of the subjects
who participated in this study. The study protocols were approved
by the Ethics Committee of the University of Occupational and
Environmental Health and included standard procedures for clin-
ical research involving vulnerable participants in Japan. This
study was performed according to the ethical standards of the
Declaration of Helsinki. If a participant exhibited a compromised
ability to consent, we excluded this individual from this study. All
participants who declined to participate or otherwise did not par-
ticipate were eligible for treatment and were not disadvantaged
in any other manner because of their lack of participation in this
study.
STATISTICAL ANALYSIS
The differences in the clinical variables between the groups were
assessed using the t-test and the χ2 test for parametric data or
using the Mann–Whitney U-test and the Fisher exact test for
non-parametric variables. Data analysis of the IGT outcome vari-
ables was conducted using t-tests and repeated-measures analysis
of variance. A multiple linear regression was employed to ana-
lyze the effect of the serum BDNF levels on the IGT scores
while adjusting for confounding factors [depression score on the
PANSS, age, estimated IQ, Chlorpromazine-equivalent (CPZ-eq),
and PANSS-T score]. The correlations between the PANSS scores,
the IGT scores, and the serum BDNF levels were evaluated using
Pearson’s correlation analysis. P-values of <0.05 were considered
to be significant. The data were analyzed using stata13.1 software
for Windows.
RESULTS
The demographic characteristics of the subjects are summarized
in Table 1. No significant differences in age, gender, estimated IQ,
or the serum BDNF levels were detected between the two groups.
GAMBLING TASK PERFORMANCE
Descriptive data for the performance on the IGT are presented
in Table 2. The schizophrenia patients displayed significantly
smaller difference scores on the advantageous minus disadvan-
tageous deck selection index and earned significantly less money
than the controls.
The learning curves of each group are shown in Figure 1.
There were significant main effects of the group (p < 0.001) and
the block (p < 0.001) and a significant group × block interaction
(p < 0.001). A follow-up independent t-test indicated that the
controls performed better than the schizophrenia patients dur-
ing the final three blocks but not during the first two blocks.
Even after correction for multiple comparisons, this between-
group difference remained statistically significant for the final
three blocks.
The between-group differences in selections from each deck
were examined using a 2 (group) × 4 (deck) repeated-measures
ANOVA. There was a significant main effect of the deck (p <
0.001) and a significant group × deck interaction (p < 0.001).
Follow-up t-tests evaluated the between-group differences in the
selection from each deck. As shown in Figure 2, the schizophre-
nia patients selected deck B more frequently and deck C less
Table 1 | Demographic and clinical information of the schizophrenia
patients and the healthy control group.
Healthy control Schizophrenia p-value
group
Age (year) 36.7±9.9 35.1±12.1 0.43
Gender (M/F) 25/26 43/43 0.91
Education (years) 13.4±2.2 12.7±2.7 0.15
Estimated IQ 101.8±7.6 99.4±8.2 0.09
Duration of the
illness (years)
11.4±13.2
SCHIZOPHRENIA DIAGNOSIS
Paranoid type 47
Disorganized type 27
Catatonic type 5
Indifferenciated type 7
PANSS-P 17.2±4.7
PANSS-N 20.4±4.6
PANSS-G 33.2±7.0
PANSS-T 70.7±11.7
CPZeq of total
antipsychotic
drugs(mg/day)
470.1±293.0
Serum BDNF(ng/ml) 14.1±7.3 11.8±7.0 0.06
PANSS-P, PANSS positive score; PANSS-N, PANSS negative score; PANSS-G,
PANSS general psychopathological score; PANSS-T, PANSS total score; CPZ-eq,
chlorpromazine-equivalent.
frequently than the controls, whereas the two groups did not
differ in the selection of decks A and D (p < 0.05, even after
the Bonferroni correction).Within-group comparisons were used
to clarify the pattern of performance; the controls selected the
advantageous decks more frequently [(C + D) − (A + B)], (t =
3.95, p < 0.001) than the patients with schizophrenia.
GAMBLING TASK PERFORMANCE, CLINICAL SYMPTOMS, AND SERUM
BDNF LEVELS
No correlation was found between the total scores and mean
net scores on the IGT and the PANSS-P, PANSS-N, or PANSS-T
(Table 3). A significant negative correlation was detected between
the mean net scores on trials 61–100 and the PANSS-G scores. A
significant negative correlation was observed between the mean
net scores on the trials in the final two blocks (61–80 and 81–100)
and the serum BDNF levels (Table 3). Table 4 shows the multiple
regression analysis results for themean net scores on each block of
the trials. Depressive symptoms and the serum BDNF levels were
significantly associated with the mean net scores on the trials in
the final two blocks.
DISCUSSION
A significant finding in the present study was that the serum
BDNF levels and depressive symptoms correlated with decision-
making. Several previous studies reported that schizophrenia
patients exhibited diminished decision-making abilities com-
pared to healthy individuals (Beninger et al., 2003; Ritter et al.,
2004; Lee et al., 2007; Kim et al., 2009; Struglia et al., 2011).
To the best of our knowledge, this is the first report to provide
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Table 2 | Iowa Gambling Task performance of the schizophrenia patients and the healthy control group.
Healthy control Schizophrenia t df p
Mean amount of money earned (yen) 219902.0±72770.1 162348.8±72369.9 4.48 135 <0.001
No. of cards chosen from deck A 17.7±6.9 18.6±6.0 −0.75 135 0.44
No. of cards chosen from deck B 26.0±12.2 34.5±11.1 −4.1 135 <0.001
No. of cards chosen from deck C 30.7±12.6 19.6±6.1 5.89 135 <0.001
No. of cards chosen from deck D 25.2±8.9 27.2±9.0 −1.21 135 0.23
Choice advantageous minus disadvantageous decks 12.2±32.6 −6.3±22.3 −3.6 135 <0.001
FIGURE 1 | Iowa Gambling Task in schizophrenia and healthy subjects.
FIGURE 2 | Number of card choice selected from each deck during the
100-card task.
evidence suggesting that the serum BDNF levels reflect decision-
making ability in patients with chronic schizophrenia. A recent
meta-analysis revealed that the serum BDNF levels in schizophre-
nia patients are lower than those in healthy individuals (Green
et al., 2011). In addition, recent studies have reported an associ-
ation between poor performance on the IGT and the volume of
several lesions in the hippocampus (Bonatti et al., 2009; Labudda
et al., 2009; Yamano et al., 2011). The expression level of BDNF
is normally high in the hippocampus. Taking these findings into
account, diminished serum BDNF level in schizophrenia patients
may reflect their poor decision-making performance. In short,
serum BDNFmay serve as a biomarker of decision-making ability
in schizophrenia patients.
Wilder et al. reported that schizophrenia patients often
selected the decks corresponding to infrequent and high-
magnitude punishments (Wilder et al., 1998). Another study
confirmed the finding that schizophrenia patients performed
poorly compared to healthy individuals and often selected cards
from the deck corresponding to high-magnitude punishments
(Shurman et al., 2005). In the present study, the schizophrenia
patients selected from good decks during the latter half of the task;
however, optimizing the selection pattern appeared to be more
difficult for the schizophrenia patients compared to the healthy
individuals. Therefore, schizophrenia patients may tend to per-
form the same pattern of changes in the selection of the decks on
the IGT as the control subjects. The magnitude of the occasional
penalties has been reported to have little impact on the pattern of
card selection.
The results in the present study are in accordance with those
of previous publications (Beninger et al., 2003; Ritter et al., 2004;
Shurman et al., 2005; Lee et al., 2007; Kim et al., 2009; Struglia
et al., 2011). In addition, the present study revealed a significant
correlation between decision-making performance and certain
psychiatric symptoms. Previous studies have reported inconsis-
tent results regarding the relationship between the IGT score
and symptoms of schizophrenia, including a significant correla-
tion to not only negative symptoms of schizophrenia (Shurman
et al., 2005) but also positive symptoms of schizophrenia (Struglia
et al., 2011). Several studies demonstrated an association between
the serum BDNF levels and severity of major depressive disor-
der (Shimizu et al., 2003; Dell’Osso et al., 2010; Kurita et al.,
2012; Yoshiumra et al., 2012). In contrast, no correlations existed
between the serum BDNF levels and severity of depression
(Karege et al., 2002b; Piccinni et al., 2008; Park et al., 2014).
Taken together, it remains controversial that severity of a depres-
sive state influences decision-making in schizophrenia patients.
In short, it is not elucidated whether serum BDNF levels reflect
or not depressive factors in schizophrenia. One study reported
that depressive symptoms are associated with QOL in schizophre-
nia (Ueoka et al., 2011). Therefore, treatment targeting depressive
symptoms may improve the QOL in schizophrenia patients.
The present study contained several limitations. First, the
patients with schizophrenia were not classified into subtypes.
Second, the schizophrenia patients were receiving various
antipsychotic medications when the IGT was performed. Third,
the number of subjects in the control group was small. Fourth,
the schizophrenia patient group was receiving antipsychotics, a
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Table 3 | Correlation between the Iowa Gambling Task performance and serum BDNF, estimated IQ, and clinical symptoms.
Mean amount of money earned (yen) 1∼20 21∼40 41∼60 61∼80 81∼100
Serum BDNF concentration (ng/ml) 0.06 0.02 0.03 0.09 0.24* 0.24*
CPZeq of total antipsychotic drugs(mg/day) 0.06 −0.05 −0.09 0.00 −0.1 −0.07
Estimate IQ 0.02 −0.06 −0.04 −0.01 −0.03 −0.06
PANSS-P 0.08 0.02 −0.08 0.00 0.02 0.02
PANSS-N 0.07 −0.03 −0.02 −0.1 −0.08 −0.02
PANSS-G 0.04 −0.03 −0.07 −0.01 −0.25* −0.23*
PANSS-T 0.08 −0.01 −0.08 −0.04 −0.17 −0.13
CPZ-eq, chlorpromazine-equivalent.
*p < 0.05.
Table 4 | Multiple regression analysis results for the mean net scores on each block of the trials.
Independent variables Multiple regression statistic
β SE t-value p-value
IGT-1 Age 0.019 0.045 0.43 0.667
CPZ-eq −0.001 0.001 −0.62 0.535
Depression 1.252 0.869 1.44 0.153
PANSS-T −0.459 0.051 −0.91 0.367
Estimated-IQ −0.399 0.060 −0.67 0.506
Serum BDNF levels 0.009 0.070 0.13 0.894
IGT-2 Age −0.050 0.054 −0.93 0.354
CPZ-eq −0.000 0.002 −0.21 0.831
Depression 0.518 1.041 0.50 0.620
PANSS-T −0.049 0.06 −0.80 0.424
Estimated-IQ −0.039 0.071 −0.55 0.584
Serum BDNF levels 0.019 0.084 0.23 0.819
IGT-3 Age −0.117 0.056 −2.07 0.042*
CPZ-eq 0.002 0.002 1.02 0.313
Depression 0.834 1.084 0.77 0.444
PANSS-T −0.040 0.063 −0.63 0.532
Estimated-IQ −0.028 0.075 −0.37 0.710
Serum BDNF levels 0.078 0.088 0.89 0.378
IGT-4 Age −0.054 0.071 −0.75 0.453
CPZ-eq −0.000 0.002 −0.10 0.919
Depression −3.502 1.376 −2.54 0.013*
PANSS-T 0.034 0.080 0.42 0.673
Estimated-IQ −0.017 0.095 −0.18 0.857
Serum BDNF levels 0.23 0.112 2.06 0.043*
IGT-5 Age −0.674 0.084 −0.81 0.423
CPZ-eq 0.000 0.003 0.09 0.929
Depression −4.686 1.619 −2.89 0.005*
PANSS-T 0.077 0.094 0.82 0.414
Estimated-IQ −0.458 0.111 −0.41 0.682
Serum BDNF levels 0.269 0.131 2.05 0.044*
PANSS-T, PANSS total score; CPZ-eq, chlorpromazine-equivalent; IGT-1: Card block 1-20; IGT-2: Card block 21-40; IGT-3: Card block 41-60; IGT-4: Card block 61-80;
IGT-5: Card block 81-100.
*p < 0.05.
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relevant problem because of the influence of the drugs on the
BDNF levels. Fifth, since we evaluated the depressive symptoms
in schizophrenia with only PANSS depressive items, we were
poorly assessed and insufficient. Last, there is increasing evidence
that sampling characteristics, several sociodemographic variables
(such as age, sex, urbanicity, BMI), life-style factors (such as food,
alcohol intake, and smoking status), somatic disease, and even
self-reported depressive symptoms are relevant determinants of
serum BDNF levels (Radka et al., 1996; Karege et al., 2002a; Bus
et al., 2011). In conclusion, both depressive symptoms and the
serum BDNF levels may be associated with the impairment of
decision-making in schizophrenia patients.
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